Verity-BCG (Strain Russian BCG-I) / Verity Pharma - LARVOL DELTA

EVER: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (clinicaltrials.gov) - P3 | N=540 | Recruiting | Sponsor: Verity Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2026 ➔ Feb 2029 | Trial primary completion date: Dec 2025 ➔ Feb 2029

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

EVER: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (clinicaltrials.gov) - P3 | N=540 | Not yet recruiting | Sponsor: Verity Pharmaceuticals Inc. | Trial completion date: Aug 2026 ➔ Jan 2026 | Initiation date: Jan 2022 ➔ Jun 2022 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Head-to-Head • Trial completion date • Trial initiation date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

"Or, petition FDA to emergency release Verity BCG , Canada approved, into usa with concomitant confirmation EVER Trial." (@MedicalNoise)

FDA event